Eryaspase May Prolong Overall and Progression-free Survival in Pancreatic Cancer

Share this content:
Researchers randomly assigned 140 patients with metastatic pancreatic cancer to receive eryaspase with standard of care FOLFOX or chemotherapy alone.
Researchers randomly assigned 140 patients with metastatic pancreatic cancer to receive eryaspase with standard of care FOLFOX or chemotherapy alone.
The following article features coverage from the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. Click here to read more of Cancer Therapy Advisor's conference coverage.

Adding eryaspase to second-line chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) regardless of asparagine synthetase (ASNS) expression among patients with pancreatic cancer, according to data presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Spain.1

Asparagine, an essential amino acid for cancer survival, is hydrolyzed by L-asparaginase (L-ASP). Eryaspase is a drug formulation that encapsulates L-ASP within red blood cells and previously demonstrated efficacy and a favorable safety profile. ASNS expression is thought to determine sensitivity to asparaginase therapy.

For this phase 2b study (ClinicalTrials.gov Identifier: NCT02195180), researchers randomly assigned 140 patients with metastatic pancreatic cancer to receive eryaspase with standard of care chemotherapy (gemcitabine or combination fluorouracil, leucovorin, and oxaliplatin [FOLFOX]) or chemotherapy alone. The primary outcome of the study was improvement of OS or PFS among patients with no or low ASNS (0/1) expression.

The 97 patients who were ASNS 0/1 demonstrated hazard ratios (HRs) of 0.62 for OS and 0.73 for PFS. Among the entire patient population, patients who received eryaspase had an OS of 26.1 weeks compared with 19 weeks for patients who only received chemotherapy (HR, 0.57; P  = .03).

The most frequently reported adverse events from treatment were asthenia, nausea, vomiting, and myelosuppression.

RELATED: Outcomes in Pancreatic Cancer Not Improved by Gemcitabine Plus Erlotinib

The researchers concluded that “the role of the ASNS expression will be further investigated. Further investigation of eryaspase in [pancreatic cancer] in a [phase 3] study is warranted.”

Read more of Cancer Therapy Advisor's coverage of the European Society of Medical Oncology (ESMO) 2017 Congress by visiting the conference page.

Reference

  1. Hammel P, Bachet J, Portales F, et al. A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180). Presented at: 2017 ESMO Congress; Madrid, Spain: September 8-12, 2017. Abstract 621PD.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters